UK Markets closed

Bavarian Nordic A/S (BVNKF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
53.000.00 (0.00%)
At close: 9:33AM EDT

Bavarian Nordic A/S

Philip Heymans Alle 3
Hellerup 2900
Denmark
45 33 26 83 83
http://www.bavarian-nordic.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees711

Key executives

NameTitlePayExercisedYear born
Dr. Paul ChaplinCEO & Pres1.16MN/A1967
Mr. Henrik Juuel M.Sc.CFO & Exec. VP445.05kN/A1965
Mr. Henrik BirkCOO & Exec. VP509.54kN/A1974
Dr. Tommi Kainu M.D., Ph.D.Exec. Officer554.35kN/A1972
Mr. Rolf Sass SørensenVP of Investor Relations & CommunicationsN/AN/AN/A
Ms. Anu Helena KernsExec. VP & Chief People OfficerN/AN/AN/A
Mr. Jean-Christophe MayExec. VP & Chief Commercial OfficerN/AN/A1967
Dr. Laurence De MoerloozeExec. VP & Chief Scientific OfficerN/AN/AN/A
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; monkeypox under the JYNNEOS name; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that is in Phase I/II clinical trial for the treatment of SARS-CoV-2; TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2- and brachyury-expressing cancers; and MVA-BN WEV that is in Phase I clinical trial for treating Equine encephalitis.It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, Canada, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is based in Hellerup, Denmark.

Corporate governance

Bavarian Nordic A/S’s ISS governance QualityScore as of 30 June 2021 is 3. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.